| Year |
Citation |
Score |
| 2019 |
Yokoyama Y, Lew ED, Seelige R, Tindall EA, Walsh C, Fagan PC, Lee JY, Nevarez R, Oh J, Tucker KD, Chen M, Diliberto A, Vaaler H, Smith KM, Albert A, et al. Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases. Cancer Research. PMID 30723115 DOI: 10.1158/0008-5472.Can-18-2022 |
0.327 |
|
| 2018 |
Yokoyama Y, Lew ED, Walsh C, Lee J, Oh J, Tindall EA, Nevarez R, Diliberto A, Ely H, Seelige R, Albert A, Bui J, Li G. Abstract A37: Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A37 |
0.322 |
|
| 2017 |
Yokoyama Y, Lew ED, Seelige R, Walsh C, Barrera M, Tindall E, Oh J, Ely H, Diliberto A, Albert A, Bui J, Li G. Abstract 4698: Immuno-oncological efficacy of RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor Cancer Research. 77: 4698-4698. DOI: 10.1158/1538-7445.Am2017-4698 |
0.324 |
|
| 2017 |
Lew ED, Tindall EA, Oh J, Walsh C, Barrera M, Ely H, Diliberto A, Yokoyama Y, Li G, Albert A. Abstract 4191: RXDX-106, a novel, selective and potent small molecule TAM (TYRO3, AXL, MER) inhibitor, demonstrates efficacy in TAM-driven tumors Cancer Research. 77: 4191-4191. DOI: 10.1158/1538-7445.Am2017-4191 |
0.422 |
|
| 2016 |
Fourgeaud L, Través PG, Tufail Y, Leal-Bailey H, Lew ED, Burrola PG, Callaway P, Zagórska A, Rothlin CV, Nimmerjahn A, Lemke G. TAM receptors regulate multiple features of microglial physiology. Nature. PMID 27049947 DOI: 10.1038/Nature17630 |
0.378 |
|
| 2015 |
Miner JJ, Daniels BP, Shrestha B, Proenca-Modena JL, Lew ED, Lazear HM, Gorman MJ, Lemke G, Klein RS, Diamond MS. The TAM receptor Mertk protects against neuroinvasive viral infection by maintaining blood-brain barrier integrity. Nature Medicine. PMID 26523970 DOI: 10.1038/Nm.3974 |
0.362 |
|
| 2015 |
Dransfield I, Zagórska A, Lew ED, Michail K, Lemke G. Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells. Cell Death & Disease. 6: e1646. PMID 25695599 DOI: 10.1038/Cddis.2015.18 |
0.406 |
|
| 2015 |
Lemke G, Lew ED. A ligand for ALK. Science Signaling. 8: fs2. PMID 25605971 DOI: 10.1126/Scisignal.Aaa5566 |
0.477 |
|
| 2014 |
Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife. 3. PMID 25265470 DOI: 10.7554/Elife.03385 |
0.49 |
|
| 2014 |
Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nature Immunology. 15: 920-8. PMID 25194421 DOI: 10.1038/Ni.2986 |
0.451 |
|
| 2014 |
Lew ED, Oh J, Burrola PG, Lax I, Zagórska A, Través PG, Schlessinger J, Lemke G. Author response: Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities Elife. DOI: 10.7554/Elife.03385.018 |
0.412 |
|
| 2013 |
Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, Rothlin CV, Naughton J, Diamond MS, Lemke G, Young JA. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host & Microbe. 14: 136-47. PMID 23954153 DOI: 10.1016/J.Chom.2013.07.005 |
0.405 |
|
| 2012 |
Burstyn-Cohen T, Lew ED, Través PG, Burrola PG, Hash JC, Lemke G. Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis. Neuron. 76: 1123-32. PMID 23259948 DOI: 10.1016/J.Neuron.2012.10.015 |
0.381 |
|
| 2009 |
Bae JH, Lew ED, Yuzawa S, Tomé F, Lax I, Schlessinger J. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell. 138: 514-24. PMID 19665973 DOI: 10.1016/J.Cell.2009.05.028 |
0.534 |
|
| 2009 |
Lew ED, Furdui CM, Anderson KS, Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Science Signaling. 2: ra6. PMID 19224897 DOI: 10.1126/Scisignal.2000021 |
0.58 |
|
| 2007 |
Lew ED, Bae JH, Rohmann E, Wollnik B, Schlessinger J. Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation. Proceedings of the National Academy of Sciences of the United States of America. 104: 19802-7. PMID 18056630 DOI: 10.1073/Pnas.0709905104 |
0.588 |
|
| 2007 |
Shams I, Rohmann E, Eswarakumar VP, Lew ED, Yuzawa S, Wollnik B, Schlessinger J, Lax I. Lacrimo-auriculo-dento-digital syndrome is caused by reduced activity of the fibroblast growth factor 10 (FGF10)-FGF receptor 2 signaling pathway. Molecular and Cellular Biology. 27: 6903-12. PMID 17682060 DOI: 10.1128/Mcb.00544-07 |
0.592 |
|
| 2006 |
Eswarakumar VP, Ozcan F, Lew ED, Bae JH, Tomé F, Booth CJ, Adams DJ, Lax I, Schlessinger J. Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proceedings of the National Academy of Sciences of the United States of America. 103: 18603-8. PMID 17132737 DOI: 10.1073/Pnas.0609157103 |
0.552 |
|
| 2006 |
Furdui CM, Lew ED, Schlessinger J, Anderson KS. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Molecular Cell. 21: 711-7. PMID 16507368 DOI: 10.1016/J.Molcel.2006.01.022 |
0.52 |
|
| 2006 |
Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nürnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CW, et al. Mutations in different components of FGF signaling in LADD syndrome. Nature Genetics. 38: 414-7. PMID 16501574 DOI: 10.1038/Ng1757 |
0.546 |
|
| 2006 |
Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nürnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CWRJ, et al. Erratum: Mutations in different components of FGF signaling in LADD syndrome Nature Genetics. 38: 495-495. DOI: 10.1038/Ng0406-495 |
0.493 |
|
| Show low-probability matches. |